Stocks · News reference
Cantor Fitzgerald analyst Carter Gould reiterates Vaxcyte (NASDAQ:PCVX) with a Overweight and announces $120 price target.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Stephen King slammed Trump’s incoming press secretary over her vaccine conspiracy theories and controversial posts.
Filed: 2026-10-09 AccNo: 0001193125-26-419174 Size: 2 MB Item 1.01: Entry into a Material Definitive Agreement Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
A new NIH-backed initiative to speed up personalized cancer vaccine development sent stocks like MRNA, BNTX, and NVAX surging Friday.